EQL Pharma AB (FRA:7JK) ROCE % : 15.93% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. EQL Pharma AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 15.93%.

EQL Pharma AB ROCE % Historical Data

The historical data trend for EQL Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB ROCE % Chart

EQL Pharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

3.90

12.51

30.88

26.01

17.92

EQL Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															14.37	21.40	14.99	20.45	15.93

EQL Pharma AB ROCE % Calculation

EQL Pharma AB's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	3.034	/	( ( (25.471 - 10.34)	+	(33.027 - 14.3) )	/ 2 )
	=	3.034	/	( (15.131	+	18.727)	/ 2 )
	=	3.034	/	16.929
	=	17.92 %

EQL Pharma AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	2.96	/	( ( (30.361 - 11.936)	+	(33.027 - 14.3) )	/ 2 )
	=	2.96	/	( ( 18.425	+	18.727 )	/ 2 )
	=	2.96	/	18.576
	=	15.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

EQL Pharma AB (FRA:7JK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

EQL Pharma AB ROCE % Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

EQL Pharma AB (FRA:7JK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EQL:Sweden

Address

Stortorget 1, 3rd Floor, Lund, SWE, 222 23

Website

http://www.eqlpharma.com

EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines